Alteogen's ALT-B4 Substance Patent Approved in Europe... Strengthening Global Exclusivity

Alteogen, a bioplatform company, announced on June 9 that its recombinant human hyaluronidase ALT-B4 has received a decision to grant a patent from the European Patent Office. Alteogen plans to complete the necessary registration procedures in each European country to finalize the patent registration.

With this patent registration, Alteogen has secured exclusive rights to ALT-B4 in Europe. The company has continuously pursued patent applications and registrations for ALT-B4, focusing on major pharmaceutical markets such as the United States and Europe. The grant of this European patent is also part of its strategy to strengthen global intellectual property rights.

Aerial view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen

ALT-B4 is the key substance in Alteogen’s subcutaneous injection (SC) formulation platform. Alteogen developed ALT-B4 using domain swapping technology, which combines domains from human-derived hyaluronidase PH20 and other types of hyaluronidase. To date, seven global pharmaceutical companies—including Merck (MSD), AstraZeneca, GlaxoSmithKline (GSK), Biogen, Daiichi Sankyo, and Intas—have signed licensing agreements for ALT-B4 and are developing subcutaneous formulation therapies utilizing this platform.

The first commercialized product developed using ALT-B4 is MSD’s Keytruda SC. This product has been sold in the United States under the name Keytruda Qurex since last year and is regarded as the first case to prove the commercialization of the ALT-B4 platform.

ALT-B4 has already been granted a substance patent in the United States, securing exclusive rights until 2043. Alteogen plans to further enhance global intellectual property protection for ALT-B4 by building a comprehensive patent portfolio, including not only substance patents but also composition and use patents, thereby strengthening the long-term competitiveness of the platform.

Tae Yeon Jeon, CEO of Alteogen, stated, "ALT-B4 was designed from the early stages of development with a multi-layered patent strategy in mind, and its success in major therapeutic markets such as the United States and Europe is now becoming tangible. We can offer our global partners a core substance supported by exclusive rights, and we will continue to reinforce the patent portfolio for ALT-B4 to further expand our global partnerships and commercialization base."

This content was produced with the assistance of AI translation services.